Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
10
ALT Quote, Financials, Valuation and Earnings
Last price:
$3.51
Seasonality move
:
-10.92%
Day range:
$3.74 - $3.91
52-week range:
$2.90 - $7.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7,417.28x
P/B ratio:
1.95x
Volume:
2.9M
Avg. volume:
3.1M
1-year change:
-35.14%
Market cap:
$438.9M
Revenue:
$41K
EPS (TTM):
-$1.02
Analysts' Opinion
-
Consensus RatingAltimmune, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $17.22, Altimmune, Inc. has an estimated upside of 378.4% from its current price of $3.80.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 71.47% downside risk from its current price of $3.80.
Fair Value
-
According to the consensus of 7 analysts, Altimmune, Inc. has 378.4% upside to fair value with a price target of $17.22 per share.
ALT vs. S&P 500
-
Over the past 5 trading days, Altimmune, Inc. has overperformed the S&P 500 by 2.17% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Altimmune, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Altimmune, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Altimmune, Inc. reported revenues of $26K.
Earnings Growth
-
Altimmune, Inc. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Altimmune, Inc. reported earnings per share of -$0.27.
Enterprise value:
213M
EV / Invested capital:
0.82x
Price / LTM sales:
7,417.28x
EV / EBIT:
--
EV / Revenue:
5,195.69x
PEG ratio (5yr expected):
-1.96x
EV / Free cash flow:
-3.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$71K
Return On Assets:
-44.7%
Net Income Margin (TTM):
-214860.98%
Return On Equity:
-52.59%
Return On Invested Capital:
-48.5%
Operating Margin:
-111126.92%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $426K | $20K | $41K | $5K | $26K | |
| Gross Profit | -$1.5M | -$218K | -$71K | -$28K | -- | |
| Operating Income | -$83.5M | -$103.2M | -$94.5M | -$24.9M | -$28.9M | |
| EBITDA | -$83M | -$102.9M | -$94.4M | -$24.8M | -$28.9M | |
| Diluted EPS | -$1.64 | -$1.34 | -$1.02 | -$0.33 | -$0.27 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $204.1M | $192.8M | $209.5M | $137.2M | $278M | |
| Total Assets | $218.9M | $206.9M | $210.6M | $139.3M | $279.9M | |
| Current Liabilities | $18.3M | $17.1M | $12.1M | $10.5M | $15M | |
| Total Liabilities | $19.7M | $21.6M | $16.5M | $15.8M | $55M | |
| Total Equity | $199.1M | $185.3M | $194.1M | $123.5M | $224.9M | |
| Total Debt | $1.1M | $672K | $175K | $1.4M | $35.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$76M | -$79.8M | -$67.5M | -$18.3M | -$19.2M | |
| Cash From Investing | $13.7M | -$28.4M | -$132.5M | $13.6M | -$79.2M | |
| Cash From Financing | $86.3M | $10M | $206.8M | $10.1M | $80.8M | |
| Free Cash Flow | -$76.1M | -$79.8M | -$67.5M | -$18.3M | -$19.2M | |
ALT
Sector
Market Cap
$438.9M
$25.1M
Price % of 52-Week High
45.34%
48.72%
Dividend Yield
0%
0%
Shareholder Yield
-45.07%
-1.6%
1-Year Price Total Return
-35.14%
-18.38%
Beta (5-Year)
0.130
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.89
200-day SMA
Sell
Level
$4.45
Bollinger Bands (100)
Sell
Level
3.89 - 5.07
Chaikin Money Flow
Sell
Level
-336M
20-day SMA
Sell
Level
$4.26
Relative Strength Index (RSI14)
Sell
Level
37.52
ADX Line
Sell
Level
18.04
Williams %R
Buy
Level
-86.9258
50-day SMA
Sell
Level
$4.47
MACD (12, 26)
Sell
Level
-0.26
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
489.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.1292)
Sell
CA Score
(Annual)
Level (-0.978)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.9877)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Stock Forecast FAQ
In the current month, ALT has received 5 Buy ratings 1 Hold ratings, and 1 Sell ratings. The ALT average analyst price target in the past 3 months is $17.22.
-
Where Will Altimmune, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Altimmune, Inc. share price will rise to $17.22 per share over the next 12 months.
-
What Do Analysts Say About Altimmune, Inc.?
Analysts are divided on their view about Altimmune, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Altimmune, Inc. is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Altimmune, Inc.'s Price Target?
The price target for Altimmune, Inc. over the next 1-year time period is forecast to be $17.22 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 1 rates the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ALT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Altimmune, Inc. is a Buy. 5 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALT?
You can purchase shares of Altimmune, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Altimmune, Inc. shares.
-
What Is The Altimmune, Inc. Share Price Today?
Altimmune, Inc. was last trading at $3.51 per share. This represents the most recent stock quote for Altimmune, Inc.. Yesterday, Altimmune, Inc. closed at $3.80 per share.
-
How To Buy Altimmune, Inc. Stock Online?
In order to purchase Altimmune, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ALT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ALT
Sector
P/E ratio
--
21.37x
PEG ratio
-1.96x
-0.01x
P/B ratio
1.95x
1.73x
Price / LTM sales
7,417.28x
1.46x
Growth Metrics
ALT
Sector
Revenue growth
420%
3.27%
Earnings growth
16.42%
12.13%
Revenue (5-year growth)
-65.33%
6.25%
Earnings forecast
-$0.24
-$0.20
Profitability
ALT
Sector
Profitability FY 2025
-$71K
$2.3M
Return on invested capital
-48.5%
-33.43%
Return on assets
-44.7%
-29.94%
Return on equity
-52.59%
-40.07%
Earnings Date
Last Earnings Date
Mar
5
Next Earnings Date
May
12
Estimated Next Earnings Date
Jun
4
Balance Sheet
ALT
Sector
Total cash
$273.5M
$24.9M
Short term investments
$95M
$23M
Total assets
$279.9M
$70.1M
Long term debt
$35.4M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
